Immix Biopharma Inc. has released a presentation highlighting its progress and market position in the treatment of relapsed/refractory AL Amyloidosis. The company reports that its investigational therapy, NXC-201, has demonstrated a 70% complete response rate in clinical trials, significantly outperforming the current standard of care, which shows a 0-10% complete response rate. The NEXICART-2 clinical trial for NXC-201 is currently over 50% enrolled, with plans for a Biologics License Application (BLA) submission in the first half of 2026 and a commercial launch anticipated in late 2026. Immix Biopharma notes a market prevalence of 34,600 patients for AL Amyloidosis, with no FDA-approved drugs currently available for this indication. The company is preparing for commercial launch through 18 high-prescribing clinical trial sites and emphasizes its experienced management and clinical team. You can access the full presentation through the link below.